Last reviewed · How we verify
VentriGel
At a glance
| Generic name | VentriGel |
|---|---|
| Sponsor | Ventrix, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS) (PHASE1)
- A Study of VentriGel in Post-MI Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VentriGel CI brief — competitive landscape report
- VentriGel updates RSS · CI watch RSS
- Ventrix, Inc. portfolio CI